UROY Fundamental Analysis - URANIUM ROYALTY CORP

Fundamental Rating

UROY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 211 industry peers in the Oil, Gas & Consumable Fuels industry. No worries on liquidiy or solvency for UROY as it has an excellent financial health rating, but there are worries on the profitability. UROY does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

UROY had negative earnings in the past year.

In the past year UROY had a positive cash flow from operations.

UROY had negative earnings in 4 of the past 5 years.

In the past 5 years UROY always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -0.66%, UROY is doing worse than 70.62% of the companies in the same industry.

With a Return On Equity value of -0.66%, UROY is not doing good in the industry: 67.77% of the companies in the same industry are doing better.

Looking at the Return On Invested Capital, with a value of 0.12%, UROY is doing worse than 75.36% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-0.66%
ROE	-0.66%
ROIC	0.12%

ROA(3y)-0.51%

ROA(5y)-1.15%

ROE(3y)-0.57%

ROE(5y)-1.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

UROY has a Operating Margin of 0.94%. This is in the lower half of the industry: UROY underperforms 73.93% of its industry peers.

UROY has a worse Gross Margin (18.11%) than 66.35% of its industry peers.

		Industry Rank	Sector Rank
OM	0.94%
PM (TTM)	N/A
GM	18.11%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

UROY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

UROY has more shares outstanding than it did 1 year ago.

The number of shares outstanding for UROY has been increased compared to 5 years ago.

The debt/assets ratio for UROY is higher compared to a year ago.

2.2 Solvency

UROY has an Altman-Z score of 361.73. This indicates that UROY is financially healthy and has little risk of bankruptcy at the moment.

UROY has a Altman-Z score of 361.73. This is amongst the best in the industry. UROY outperforms 99.05% of its industry peers.

The Debt to FCF ratio of UROY is 0.01, which is an excellent value as it means it would take UROY, only 0.01 years of fcf income to pay off all of its debts.

UROY's Debt to FCF ratio of 0.01 is amongst the best of the industry. UROY outperforms 92.89% of its industry peers.

A Debt/Equity ratio of 0.00 indicates that UROY is not too dependend on debt financing.

UROY has a better Debt to Equity ratio (0.00) than 84.36% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.01
Altman-Z	361.73

ROIC/WACC0.02

WACC8.12%

2.3 Liquidity

UROY has a Current Ratio of 201.73. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.

UROY has a Current ratio of 201.73. This is amongst the best in the industry. UROY outperforms 100.00% of its industry peers.

A Quick Ratio of 41.86 indicates that UROY has no problem at all paying its short term obligations.

The Quick ratio of UROY (41.86) is better than 98.58% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	201.73
Quick Ratio	41.86

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

UROY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.00%.

Looking at the last year, UROY shows a quite strong growth in Revenue. The Revenue has grown by 14.29% in the last year.

EPS 1Y (TTM)-117%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%157%

Revenue 1Y (TTM)14.29%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

UROY is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -148.34% yearly.

Based on estimates for the next years, UROY will show a very negative growth in Revenue. The Revenue will decrease by -37.41% on average per year.

EPS Next Y700.6%

EPS Next 2Y-246.58%

EPS Next 3Y-148.34%

EPS Next 5YN/A

Revenue Next Year174.39%

Revenue Next 2Y-75.5%

Revenue Next 3Y-37.41%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

UROY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year UROY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

74.88% of the companies in the same industry are cheaper than UROY, based on the Enterprise Value to EBITDA ratio.

The rest of the industry has a similar Price/Free Cash Flow ratio as UROY.

		Industry Rank	Sector Rank
P/FCF	54.05
EV/EBITDA	1135.95

4.3 Compensation for Growth

UROY's earnings are expected to decrease with -148.34% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-246.58%

EPS Next 3Y-148.34%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

UROY does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

URANIUM ROYALTY CORP

NASDAQ:UROY (10/7/2025, 4:34:48 PM)

After market: 4.25 +0.04 (+0.95%)

4.21

-0.06 (-1.41%)

Chartmill FA Rating

GICS SectorEnergy

GICS IndustryGroupEnergy

GICS IndustryOil, Gas & Consumable Fuels

Earnings (Last)09-11 2025-09-11

Earnings (Next)12-10 2025-12-10

Inst Owners28.31%

Inst Owner Change0%

Ins Owners2.18%

Ins Owner ChangeN/A

Market Cap562.62M

Analysts75

Price Target3.84 (-8.79%)

Short Float %8.89%

Short Ratio3.2

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)12.45%

PT rev (3m)10.36%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-50%

EPS NY rev (3m)219.98%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-9.86%

Revenue NY rev (3m)180.32%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	16.09
P/FCF	54.05
P/OCF	36.07
P/B	2.64
P/tB	2.64
EV/EBITDA	1135.95

EPS(TTM)-0.01

EYN/A

EPS(NY)-0.03

Fwd EYN/A

FCF(TTM)0.08

FCFY1.85%

OCF(TTM)0.12

OCFY2.77%

SpS0.26

BVpS1.59

TBVpS1.59

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.66%
ROE	-0.66%
ROCE	0.16%
ROIC	0.12%
ROICexc	0.15%
ROICexgc	0.15%
OM	0.94%
PM (TTM)	N/A
GM	18.11%
FCFM	29.77%

ROA(3y)-0.51%

ROA(5y)-1.15%

ROE(3y)-0.57%

ROE(5y)-1.22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.16

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0.01
Debt/EBITDA	0.22
Cap/Depr	4472.22%
Cap/Sales	14.84%
Interest Coverage	250
Cash Conversion	3495.51%
Profit Quality	N/A
Current Ratio	201.73
Quick Ratio	41.86
Altman-Z	361.73

F-Score5

WACC8.12%

ROIC/WACC0.02

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-117%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%157%

EPS Next Y700.6%

EPS Next 2Y-246.58%

EPS Next 3Y-148.34%

EPS Next 5YN/A

Revenue 1Y (TTM)14.29%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year174.39%

Revenue Next 2Y-75.5%

Revenue Next 3Y-37.41%

Revenue Next 5YN/A

EBIT growth 1Y-92.79%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year142.68%

EBIT Next 3Y3.56%

EBIT Next 5YN/A

FCF growth 1Y345.89%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y468.48%

OCF growth 3YN/A

OCF growth 5YN/A

URANIUM ROYALTY CORP (UROY) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens